Redixivir is essentially a nucleoside analogue with antiviral activity.
On June 365438+1October 3 1 day, 2020, the authoritative medical journal NEJM published many papers about novel coronavirus (20 19-nCoV) online. One of the articles introduces the diagnosis and treatment process and clinical manifestations of the first confirmed case in the United States. During the diagnosis and treatment of this patient, a drug named remdesivir was mentioned, which showed a good effect in anti-novel coronavirus. However, due to insufficient clinical data and low sample content, its effectiveness cannot be further verified by large-scale clinical trials.
Remdesivir is a drug under research, which has not been approved for marketing in any country before, and its safety and effectiveness have not been confirmed, so there is no data of 20 19-nCoV. In the absence of any approved treatment plan, after weighing the risks and benefits, the attending doctor put forward the requirements for medication and tried to use it. With the support of local regulatory authorities, it is used for emergency treatment of a small number of 20 19-nCoV infected people.
Up to now, there are more and more data on the treatment of novel coronavirus patients with this drug. On July 3rd, EU officially approved medical institutions to use Remdesivir to treat COVID-19. ?
According to the current clinical data, Redsivil can obviously shorten the rehabilitation time and treatment time of novel coronavirus patients, and reduce the pressure of medical institutions. According to the related literature of NEJM, the symptoms of patients in novel coronavirus who use raloxivir can be significantly improved within a short course of treatment of 5 days at the earliest, and most patients can be significantly improved after treatment 14 days.
According to related news reports, the Korean government also decided to put Remdesivir into the treatment of novel coronavirus patients on July 2nd.